posted on 2025-07-31, 20:45authored byA Sifrim, M-P Hitz, A Wilsdon, J Breckpot, SHA Turki, B Thienpont, J McRae, TW Fitzgerald, T Singh, GJ Swaminathan, E Prigmore, D Rajan, H Abdul-Khaliq, S Banka, UMM Bauer, J Bentham, F Berger, S Bhattacharya, F Bu'Lock, N Canham, I-G Colgiu, C Cosgrove, H Cox, I Daehnert, A Daly, J Danesh, A Fryer, M Gewillig, E Hobson, K Hoff, T Homfray, INTERVAL Study, A-K Kahlert, A Ketley, H-H Kramer, K Lachlan, AK Lampe, JJ Louw, AK Manickara, D Manase, KP McCarthy, K Metcalfe, C Moore, R Newbury-Ecob, SO Omer, WH Ouwehand, S-M Park, MJ Parker, T Pickardt, MO Pollard, L Robert, DJ Roberts, J Sambrook, K Setchfield, B Stiller, C Thornborough, O Toka, H Watkins, D Williams, M Wright, S Mital, PEF Daubeney, B Keavney, J Goodship, RM Abu-Sulaiman, S Klaassen, CF Wright, HV Firth, JC Barrett, K Devriendt, DR FitzPatrick, JD Brook, Deciphering Developmental Disorders Study, ME Hurles
Congenital heart defects (CHDs) have a neonatal incidence of 0.8-1% (refs. 1,2). Despite abundant examples of monogenic CHD in humans and mice, CHD has a low absolute sibling recurrence risk (∼2.7%), suggesting a considerable role for de novo mutations (DNMs) and/or incomplete penetrance. De novo protein-truncating variants (PTVs) have been shown to be enriched among the 10% of 'syndromic' patients with extra-cardiac manifestations. We exome sequenced 1,891 probands, including both syndromic CHD (S-CHD, n = 610) and nonsyndromic CHD (NS-CHD, n = 1,281). In S-CHD, we confirmed a significant enrichment of de novo PTVs but not inherited PTVs in known CHD-associated genes, consistent with recent findings. Conversely, in NS-CHD we observed significant enrichment of PTVs inherited from unaffected parents in CHD-associated genes. We identified three genome-wide significant S-CHD disorders caused by DNMs in CHD4, CDK13 and PRKD1. Our study finds evidence for distinct genetic architectures underlying the low sibling recurrence risk in S-CHD and NS-CHD.